Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 20:10 | 2026-04-29 | AIMD | Ainos, Inc. | chiang yao-chung | Director | BUY | $1.70 | 300 | $511 | 700 |
| 2026-05-02 01:34 | 2026-05-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Officer | OPT+S | $71.50 | 78,333 | $5,600,700 | 0 |
| 2026-05-02 01:35 | 2026-05-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer | OPT+S | $71.37 | 12,500 | $892,125 | 97,994 |
| 2026-05-02 01:34 | 2026-05-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer | SELL | $71.37 | 15,000 | $1,070,507 | 612,540 |
| 2026-05-02 01:05 | 2026-05-01 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | OPT+S | $33.40 | 9,000 | $300,560 | 81,389 |
| 2026-05-01 23:30 | 2026-04-29 | PHVS | Pharvaris N.V. | Lesage Anne | Officer | OPT+S | $30.23 | 48,300 | $1,459,969 | 133,969 |
| 2026-05-01 23:32 | 2026-04-29 | PHVS | Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | Director | SELL | $30.29 | 32,900 | $996,544 | 355,167 |
| 2026-05-01 23:09 | 2026-04-29 | PHVS | Pharvaris N.V. | Lu Peng | Officer | OPT+S | $30.21 | 18,733 | $565,858 | 66,083 |
| 2026-05-01 22:50 | 2026-05-01 | AVLN | Avalyn Pharma Inc. | Carroll Jill | Director | BUY | $18.00 | 277,778 | $5,000,004 | 2,186,562 |
| 2026-05-01 22:46 | 2026-05-01 | AVLN | Avalyn Pharma Inc. | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | BUY | $18.00 | 555,555 | $9,999,990 | 1,122,087 |
| 2026-05-01 22:25 | 2026-05-01 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | Officer | OPT+S | $63.88 | 5,000 | $319,385 | 236,984 |
| 2026-05-01 21:50 | 2026-05-01 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | SELL | $16.76 | 5,394 | $90,407 | 26,453 |
| 2026-05-01 21:50 | 2026-05-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer | SELL | $6.23 | 16,667 | $103,805 | 1,193,173 |
| 2026-05-01 21:42 | 2026-05-01 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Officer | SELL | $13.12 | 4,170 | $54,694 | 143,542 |
| 2026-05-01 20:56 | 2026-04-30 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $572.61 | 10,000 | $5,726,062 | 18,876 |
| 2026-05-01 20:57 | 2026-04-30 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $572.63 | 9,500 | $5,439,991 | 40,513 |
| 2026-05-01 20:34 | 2026-04-30 | PCSA | Processa Pharmaceuticals, Inc. | Bigora Sian | Officer | BUY | $2.69 | 1,986 | $5,342 | 7,496 |
| 2026-05-01 20:35 | 2026-04-30 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Officer | BUY | $2.69 | 1,748 | $4,702 | 6,441 |
| 2026-05-01 20:36 | 2026-04-30 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Officer | BUY | $2.69 | 1,511 | $4,065 | 6,236 |
| 2026-05-01 20:37 | 2026-04-30 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | Director, Officer | BUY | $2.69 | 2,034 | $5,471 | 6,013 |
| 2026-05-01 20:37 | 2026-04-29 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Officer | SELL | $13.16 | 16,915 | $222,590 | 423 |
| 2026-05-01 20:38 | 2026-04-30 | PCSA | Processa Pharmaceuticals, Inc. | SKIBSTED RUSSELL | Officer | BUY | $2.69 | 2,190 | $5,891 | 6,498 |
| 2026-05-01 20:39 | 2026-04-30 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Director, Officer | BUY | $2.69 | 1,706 | $4,589 | 13,813 |
| 2026-05-01 20:30 | 2026-04-29 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $99.55 | 5,500 | $547,524 | 58,117 |
| 2026-05-01 20:30 | 2026-04-30 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | OPT+S | $99.22 | 5,500 | $545,691 | 59,634 |
| 2026-05-01 20:32 | 2026-05-01 | KNSA | Kiniksa Pharmaceuticals International, plc | Patel Sanj K | Director, Officer | OPT+S | $54.02 | 48,565 | $2,623,481 | 0 |
| 2026-05-01 20:15 | 2026-04-30 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $156.97 | 1,000 | $156,973 | 4,666 |
| 2026-04-30 23:20 | 2026-04-28 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $53.86 | 21,120 | $1,137,593 | 74,760 |
| 2026-04-30 22:33 | 2026-04-28 | KNSA | Kiniksa Pharmaceuticals International, plc | Patel Sanj K | Director, Officer | OPT+S | $51.96 | 508,339 | $26,415,226 | 0 |
| 2026-04-30 21:54 | 2026-04-28 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $49.78 | 34,791 | $1,731,840 | 40,136 |
| 2026-04-30 21:54 | 2026-04-28 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $5.78 | 19,497 | $112,778 | 277,569 |
| 2026-04-30 21:35 | 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Officer | OPT+S | $16.65 | 3,214 | $53,498 | 120,399 |
| 2026-04-30 21:37 | 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $16.65 | 3,214 | $53,498 | 31,847 |
| 2026-04-30 21:38 | 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | Officer | OPT+S | $16.65 | 2,388 | $39,749 | 51,647 |
| 2026-04-30 21:22 | 2026-04-28 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Director | SELL | $18.38 | 227,337 | $4,178,522 | 1,158,923 |
| 2026-04-30 20:30 | 2026-04-29 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $571.22 | 9,500 | $5,426,598 | 40,513 |
| 2026-04-30 20:32 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | Director, Officer | BUY | $2.54 | 2,136 | $5,415 | 2,136 |
| 2026-04-30 20:33 | 2026-04-15 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | Director, Officer | BUY | $2.97 | 1,843 | $5,474 | 3,979 |
| 2026-04-30 20:07 | 2026-04-28 | DRUG | BRIGHT MINDS BIOSCIENCES INC. | Cormorant Asset Management, LP | SELL | $89.50 | 109,331 | $9,785,125 | 950,000 | |
| 2026-04-30 20:15 | 2026-04-29 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $155.82 | 1,000 | $155,817 | 5,666 |
| 2026-04-29 20:05 | 2026-04-27 | NCEL | NewcelX Ltd. | Samuel Olivier | Director | BUY | $2.75 | 81,818 | $225,000 | 81,818 |
| 2026-04-29 20:05 | 2026-04-27 | NCEL | NewcelX Ltd. | Revel Michel | Director, Officer, 10% owner | BUY | $2.75 | 54,545 | $149,999 | 957,530 |
| 2026-04-29 23:21 | 2026-04-28 | ZBIO | Zenas BioPharma, Inc. | MOULDER LEON O JR | Director, Officer | BUY | $17.79 | 60,000 | $1,067,202 | 1,786,039 |
| 2026-04-29 23:16 | 2026-04-27 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.75 | 205,911 | $154,516 | 1,953,949 |
| 2026-04-29 20:46 | 2026-04-28 | KNSA | Kiniksa Pharmaceuticals International, plc | Quart Barry D | Director | OPT+S | $50.10 | 13,099 | $656,260 | 12,546 |
| 2026-04-29 20:23 | 2026-04-29 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $59.62 | 7,500 | $447,150 | 407,830 |
| 2026-04-29 20:30 | 2026-04-27 | LQDA | Liquidia Corp | Adair Jason | Officer | SELL | $41.65 | 688 | $28,655 | 214,738 |
| 2026-04-29 20:30 | 2026-04-27 | MPLT | MapLight Therapeutics, Inc. | Kreitzer Anatol | Officer | SELL | $29.66 | 45,422 | $1,347,067 | 211,190 |
| 2026-04-29 20:30 | 2026-04-27 | MPLT | MapLight Therapeutics, Inc. | GILLIS JONATHAN | Officer | SELL | $29.89 | 69,835 | $2,087,689 | 181,219 |
| 2026-04-29 20:31 | 2026-04-28 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $568.04 | 9,500 | $5,396,353 | 40,513 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.